ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Sub-retinal pigment epithelium features as predictors for limited interval extension of faricimab in treatment-naïve neovascular age-related macular degeneration.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore subtypes of macular neovascularization (MNV) and anatomical features predictive for limited interval extension of faricimab injections in treatment-naïve neovascular age-related macular degeneration (nAMD).
methodsThis retrospective study evaluated 82 eyes of 78 patients initiating treatment with faricimab using a treat-and-extend regimen. Age and best-corrected visual acuity (BCVA) were extracted from medical records. Optical coherence tomography parameters including central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximum pigment epithelial detachment (PED) height were measured.
resultsAt one year, 63 eyes (76.8%) continued faricimab treatment, while 19 eyes (23.2%) discontinued due to inability to maintain ≥ 8-week intervals. Discontinued eyes exhibited significantly greater baseline maximum PED height (P = 0.012). Eyes achieving intervals ≥ 12 weeks (extended group, n = 40) were compared with those not achieving this criterion (non-extended group, n = 42). Post hoc residual analysis revealed that type 1 MNV without polypoidal lesions was significantly overrepresented in the non-extended group (P = 0.033). Multivariable logistic regression analysis confirmed that greater baseline maximum PED height was the only independent predictor of limited interval extension (odds ratio, 0.965 per 10-µm increase; 95% confidence interval, 0.935-0.995; P = 0.021). Other baseline factors, including age, BCVA, CRT, and SFCT, showed no significant association.
conclusionSub-RPE features at baseline, specifically type 1 MNV without polypoidal lesions and greater PED height, are significant predictors of limited treatment interval extension in treatment-naïve nAMD eyes receiving faricimab. Recognizing these features prior to treatment initiation may guide clinical decision-making regarding injection frequency.
Indexed as
Identifiers
42262543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.